Skip to main content

Bisphosphonates and Esophageal Cancer: No Link Seen


LAS VEGAS, Nevada — Bisphosphonates (BPs) are not associated with an increased risk for esophageal cancer, according to a study presented here at the American College of Gastroenterology (ACG) 2012 Annual Scientific Meeting and Postgraduate Course.
Oral BPs are commonly used to prevent and treat osteoporosis, but they can cause erosive esophagitis when pills become entrapped in the esophagus. Some previous studies had suggested an association between long-term BP use and an increased risk for esophageal cancer, but there were conflicting results.
"Some people are concerned that esophagitis might cause inflammation and lead to (cancer)," presenter Saowanee Ngamruengphong, MD, a gastrointestinal fellow at the Mayo Clinic in Jacksonville, Florida, told Medscape Medical News.
The researchers performed a systematic review and meta-analysis of controlled observational studies. MEDLINE was searched from 1950 to 2012, and bibliographies of all retrieved articles were examined. They included all controlled observational studies that compared esophageal cancer outcome in patients using BPs with control groups.
A random effects model was used to calculate pooled odds ratios (ORs) and 95% confidence intervals (CIs) from adjusted effect estimates with standard error. Heterogeneity of the effects was determined using the Cochrane Q X2 test.
Of the 42 studies identified, 6 studies (3 cohort, 3 case-controlled) with 3570 esophageal cancer patients were selected for analysis. Five of the studies were conducted in western countries. The pooled OR for BP users, compared with nonusers, was 1.02 (95% CI, 0.73 - 1.42). No significant heterogeneity between studies was found (P = .15).
The researchers also conducted a sensitivity analysis and found that the pooled OR of the case-controlled studies was marginally significant (OR, 1.28; 95% CI, 1.01 - 1.63).
"We don't see any risk of bisphosphonate-induced esophageal cancer. If patients really need to be on bisphosphonates for bone disease, you should not stop it based on fear of esophageal cancer," said Dr. Ngamruengphong.
"(The finding) makes sense to me," Yvonne Romero, MD, an esophagologist at Mayo Clinic in Rochester, Minnesota, who was not involved in the study, told Medscape Medical News. "I see these little old ladies who want to take aspirin with just enough water to get it down. They don't realize they're taking a risk. If the pill makes it to the stomach, fabulous. But if it stays in the esophagus, it will burn and cause pill esophagitis. Drugs that do that include aspirin, ibuprofen, iron supplements, and bisphosphonates."
It is likely that studies suggesting an association between pill esophagitis and esophageal cancer were really showing that patients taking BPs were occasionally going to the emergency department for pill esophagitis, which is often quite painful. Once there, patients would be examined by physicians, and if they had esophageal cancer, it would be discovered. "It wasn't that bisphosphonates caused the cancer — they just brought it to (the physician's) attention. That's what this meta-analysis shows," said Dr. Romero.
Dr. Ngamruengphong and Dr. Romero have disclosed no relevant financial relationships.
American College of Gastroenterology (ACG) 2012 Annual Scientific Meeting and Postgraduate Course: Abstract P577. Presented October 22, 2012.

Comments

Post a Comment

Popular posts from this blog

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such...
Post a Comment
Read more

FDA Approvals: Pazopanib for Advanced Soft Tissue Sarcoma

CLINICAL CONTEXT Pazopanib was first approved by the US Food and Drug Administration (FDA) in 2009 when it became the sixth drug approved to treat advanced renal cell carcinoma. It is a small molecule with a mechanism of action as a tyrosine kinase inhibitor, specifically targeting receptors involved in angiogenesis and tumor cell proliferation. These include vascular endothelial growth-factor receptors 1, 2, and 3; platelet-derived growth-factor receptors α and β; fibroblast growth-factor receptors 1 and 3; stem cell factor receptors; interleukin-2-inducible T-cell kinase; leukocyte-specific protein tyrosine kinase; and transmembrane glycoprotein-receptor tyrosine kinase. STUDY SYNOPSIS AND PERSPECTIVE The FDA has approved pazopanib ( Votrient ) for the treatment of advanced soft tissue sarcoma in patients who have received previous chemotherapy. Pazopanib is already marketed for the treatment of advanced renal cell carcinoma; when it was approved in 2009, it became the six...
Post a Comment
Read more

CareFusion Issues Update on Infant Breathing Product Recall

July 5, 2012 — Medical device maker CareFusion has issued an update reminding healthcare providers of its voluntary recall of its Air Life ™ Infant Breathing Circuit, initiated back in May. The US Food and Drug Administration (FDA) has classified this action as a class 1 recall, meaning there is a reasonable probability of serious adverse health consequences or death associated with use of the defective units. The update was posted July 2 on the FDA  Website. On May 29, 2012, CareFusion sent an  Urgent Recall Notice  to customers and distributors stating that the company had identified potential risks associated with the Air Life  Infant Breathing Circuit. The action was initiated after the company received complaints of the Y adapter within the breathing circuit developing cracks during patient use. "If a crack develops in the Y adapter, this could potentially result in a leak in the closed ventilation system, leading to a loss in the intended tidal volum...
Post a Comment
Read more